Auris Medical Holding AG (NASDAQ:EARS) shares dropped 1.9% during mid-day trading on Monday . The company traded as low as $4.50 and last traded at $4.53, with a volume of 65,377 shares changing hands. The stock had previously closed at $4.62.

EARS has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, July 12th. Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Finally, Leerink Swann restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Thursday, May 12th.

The stock has a 50 day moving average of $4.01 and a 200-day moving average of $3.96. The company’s market cap is $154.14 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. During the same quarter in the prior year, the business posted ($0.28) EPS. Equities research analysts predict that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.